Price chart (1D to 10Y)
Licensed market data — shown to members, not published to the open web.
Valuation vs Instaport thresholds (P/E, PEG, P/FCF, P/S)
Licensed market data — shown to members, not published to the open web.
Profile
From SEC filingsCompany description
Nuwellis is dedicated to advancing cardiorenal care by enabling earlier, safer, and more controlled fluid management for patients. The company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow® and the Aquadex SmartFlow® systems (collectively the “Aquadex System”). The Aquadex SmartFlow® system is indicated for temporary (up to eight hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. Please note that selected authors in the citations below are either current consultants to the Company or were previously compensated consultants. Each author typically is required to disclose any actual or potential conflicts of interest at the time they submitted their written manuscript to the potential publication. Dr. Sean Pinney for example, was the principal investigator under the Company’s former REVERSE-HF heart failure clinical study. Additionally, Dr. Maria Rosa Costanzo, joined the Company’s Board of Directors in September 2019, though many of her cited publications preceded her membership on the Board of Directors. She resigned from the Board of Directors on January 21, 2026, which was not the result of any disagreement with Nuwellis regarding its operations, policies, or practices. Since joining the Company’s Board, Dr.
Read the full filing description · filed 11 Mar 2026
At a glance
- Sector
- Healthcare
- Industry
- Electromedical & Electrotherapeutic Apparatus
Source: SEC filings. Information and analytics, not investment advice.